Yayın:
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study

dc.contributor.authorTurhal, N. S.
dc.contributor.authorHasan Şenol Çoşkun
dc.contributor.authorFaysal Dane
dc.contributor.authorBülent Karabulut
dc.contributor.authorLevent Korkmaz
dc.contributor.authorMustafa Karaağaç
dc.contributor.authorDevrim Çabuk
dc.contributor.authorSenem Karabulut
dc.contributor.authorNuri Faruk Aykan
dc.contributor.authorHatice Doruk
dc.contributor.authorNilüfer Avcı
dc.contributor.authorN. S. Turhal
dc.contributor.orcid0000-0003-2335-3354
dc.contributor.orcid0000-0003-2969-7561
dc.contributor.orcid0000-0001-6584-902X
dc.contributor.orcid0000-0002-1949-8334
dc.contributor.orcid0000-0001-6931-6896
dc.contributor.orcid0000-0003-4533-0620
dc.contributor.orcid0000-0002-7871-6311
dc.contributor.orcid0000-0003-4740-9973
dc.contributor.orcid0000-0002-5472-3218
dc.contributor.orcid0000-0002-1013-5676
dc.date.accessioned2025-11-13T22:20:32Z
dc.date.issued2016-04-29
dc.identifier.doihttps://doi.org/10.1007/s12029-016-9823-7
dc.identifier.endpage272
dc.identifier.issn1941-6628
dc.identifier.issue3
dc.identifier.openalexW2342916534
dc.identifier.startpage264
dc.identifier.urihttps://hdl.handle.net/11421/13865
dc.identifier.urihttps://doi.org/10.1007/s12029-016-9823-7
dc.identifier.volume47
dc.language.isoen
dc.relation.ispartofJournal of Gastrointestinal Cancer
dc.rightsrestrictedAccess
dc.subjectBevacizumab
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectIrinotecan
dc.subjectOxaliplatin
dc.subjectColorectal cancer
dc.subjectOncology
dc.subjectCapecitabine
dc.subjectKRAS
dc.subjectChemotherapy
dc.subjectCetuximab
dc.subjectProgression-free survival
dc.subjectCancer
dc.subject.sdg3
dc.titleBenefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5064011743

Dosyalar

Koleksiyonlar